CME Group
CME
$255.94
+1.55%
CME Group Inc. operates the world's leading and most diverse derivatives marketplace, providing a platform for trading futures and options contracts across interest rates, equity indexes, foreign exchange, energy, agricultural products, and metals. The company is a dominant global market infrastructure player, leveraging its massive scale, network effects, and ownership of benchmark contracts like the S&P 500 futures to create a formidable competitive moat. The current investor narrative is heavily influenced by macroeconomic uncertainty, as CME's revenue is directly tied to trading volumes driven by volatility in interest rates and inflation, with recent news highlighting its strategic appeal to large investors like Alphabet and its robust dividend payouts amidst a challenging rate environment.…
CME
CME Group
$255.94
Related headlines
Investment Opinion: Should I buy CME Today?
Rating & Thesis: Hold. CME is a high-quality franchise caught in a cyclical downdraft, where the compelling long-term fundamentals are currently offset by near-term technical damage and valuation risk, warranting a wait-and-see approach. This aligns with the mixed analyst consensus showing no strong directional conviction.
Supporting Evidence: The hold rating is supported by four key data points: 1) The stock trades at a forward P/E of 19.8x, a discount to its trailing multiple but still at a premium to many peers, limiting near-term upside. 2) Revenue growth, while positive at 8.1% YoY in Q4, shows signs of volatility and deceleration. 3) Profitability remains stellar with net margins above 70%, and cash flow generation at $4.2B TTM is robust. 4) Technically, the stock is in a severe downtrend (-19.3% over 3 months) and sits just 4.7% above its 52-week low, suggesting momentum is strongly negative.
Risks & Conditions: The two biggest risks are a prolonged slump in trading volumes compressing earnings, and multiple contraction if the premium valuation is not justified by growth. This Hold would upgrade to a Buy if the stock stabilizes above key technical support ($244.56) and shows sustained quarterly revenue re-acceleration above 10% YoY. It would downgrade to a Sell if it breaks below the 52-week low on high volume or if forward earnings estimates are meaningfully cut. Relative to its own history and the uncertainty in its growth trajectory, the stock is currently fairly valued to slightly overvalued.
Sign up to view all
CME 12-Month Price Forecast
The AI assessment is neutral based on the offsetting forces of world-class business quality against clear near-term headwinds. The stock's high margins and cash flow generation are undeniable strengths, but they are currently priced in, with the forward P/E not signaling deep value. The severe technical downtrend and lack of positive momentum are significant concerns that cannot be ignored. The stance would upgrade to bullish on a confirmed technical reversal (e.g., a sustained move above the 200-day moving average) coupled with accelerating quarterly revenue growth. It would turn bearish if the stock breaks key support at $244.56 on high volume, signaling a failure of the current fundamental floor.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CME Group's 12-month outlook, with a consensus price target around $332.72 and implied upside of +30.0% versus the current price.
Average Target
$332.72
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$205 - $333
Analyst target range
Coverage is limited with only 7 analysts, and the consensus sentiment appears mixed given recent rating actions; the distribution includes Buy (TD Cowen, Morgan Stanley), Hold/Equal Weight (Argus, RBC, Barclays), and Sell (JP Morgan Underweight), indicating a lack of strong directional conviction. The average revenue estimate for the upcoming period is $8.68 billion, with a range from $8.40 billion to $8.91 billion, but a specific consensus price target is not provided in the data, preventing calculation of implied upside/downside from the current price of $256.06. The recent institutional rating actions show a downgrade from Argus Research (Buy to Hold) in March 2026, but also an upgrade from TD Cowen (Hold to Buy) in January 2026, highlighting the ongoing debate and uncertainty regarding the stock's outlook amidst macroeconomic crosscurrents.
Bulls vs Bears: CME Investment Factors
The investment debate for CME is a classic clash between exceptional, high-moat fundamentals and severe near-term price deterioration. The bull case, supported by a 70.8% net margin, $4.2B in annual FCF, and a pristine balance sheet, appears to have stronger underlying evidence of business quality. However, the bear case currently dominates market sentiment, as evidenced by a 19.3% three-month decline and trading near 52-week lows. The single most important tension is whether the current price action represents a compelling value opportunity in a world-class franchise or a justified derating due to cyclical revenue headwinds and a premium valuation. The resolution hinges on the trajectory of trading volumes and whether they can re-accelerate to justify the stock's still-elevated multiples.
Bullish
- Exceptional Profitability & Cash Flow: CME's business model generates extraordinary margins, with a Q4 2025 net margin of 70.84% and a gross margin of 85.38%. This translates into massive free cash flow of $4.19 billion TTM, which funds substantial shareholder returns, including dividends and buybacks, as evidenced by a payout ratio of 97.2%.
- Dominant Market Position & Moat: As the world's leading derivatives exchange with ownership of benchmark contracts like S&P 500 futures, CME benefits from powerful network effects and scale. This strategic appeal is recognized by sophisticated investors, as highlighted by recent news of Alphabet making it a top holding.
- Strong Financial Health & Low Debt: The company's balance sheet is fortress-like, with a debt-to-equity ratio of only 0.13 and an exceptionally high current ratio of 93.0. This provides significant resilience and financial flexibility to navigate market downturns and pursue strategic opportunities.
- Macro Volatility as a Revenue Catalyst: CME's revenue is directly tied to trading volumes driven by interest rate and inflation uncertainty. With recent news highlighting persistent inflation and potential Fed rate hikes, the environment for heightened volatility and trading activity is supportive of future revenue growth.
Bearish
- Severe Technical Downtrend & Underperformance: The stock is in a pronounced downtrend, down 19.25% over the last three months and 7.85% over the past year, severely underperforming the SPY by 31.8 and 34.9 percentage points, respectively. It is trading near its 52-week low, indicating deep market pessimism and a lack of positive momentum.
- Revenue Volatility & Potential Deceleration: While Q4 2025 revenue grew 8.09% YoY, it declined sequentially from Q2 2025's $1.69 billion to $1.65 billion. This volatility in trading fee income, which constitutes over 80% of revenue, highlights the business's sensitivity to unpredictable market conditions and cyclicality.
- Premium Valuation Relative to Peers: CME's trailing P/E of 24.28x is noted as being above typical financial data & exchange peers. Combined with a high Price-to-Sales ratio of 15.06x, this premium valuation leaves the stock vulnerable to multiple compression if growth expectations are not met.
- Mixed & Uncertain Analyst Sentiment: Analyst coverage shows a lack of conviction, with a split between Buy, Hold, and Sell ratings and recent contradictory actions (Argus downgraded to Hold in March 2026, TD Cowen upgraded to Buy in January 2026). This reflects significant uncertainty about the near-term outlook.
CME Technical Analysis
The stock is in a pronounced downtrend, having declined 7.85% over the past year and a severe 19.25% over the last three months, significantly underperforming the SPY's 27.04% and 12.6% gains over the same periods, respectively. Currently trading at $256.06, the price sits at just 10.4% of its 52-week range ($244.56 to $329.16), indicating it is hovering near its annual lows, which suggests deep pessimism but may also present a potential value opportunity if fundamentals stabilize. Recent momentum is decisively negative, with a 10.72% drop over the past month, accelerating the longer-term downtrend and reflecting a sharp loss of confidence, as evidenced by a relative strength reading of -15.32 against the market over the same period. Key technical support is clearly defined at the 52-week low of $244.56, while resistance lies at the recent highs near $329.16; a breakdown below support could signal a capitulation phase, while a recovery above the $290-$300 zone would be needed to suggest a trend reversal. The stock's low beta of 0.26 indicates it is historically 74% less volatile than the broader market, which is unusual given its recent sharp decline and suggests this sell-off may be driven by idiosyncratic or sector-specific factors rather than broad market risk.
Beta
0.24
0.24x market volatility
Max Drawdown
-23.3%
Largest decline past year
52-Week Range
$245-$329
Price range past year
Annual Return
-4.6%
Cumulative gain past year
| Period | CME Return | S&P 500 |
|---|---|---|
| 1m | -9.0% | -0.1% |
| 3m | -15.6% | +9.0% |
| 6m | -6.0% | +7.0% |
| 1y | -4.6% | +22.9% |
| ytd | -5.1% | +8.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CME Fundamental Analysis
Revenue growth has been positive but shows signs of deceleration; Q4 2025 revenue of $1.65 billion grew 8.09% year-over-year, yet this follows a sequential decline from Q2 2025's $1.69 billion, indicating potential volatility in trading fee income which constitutes the bulk ($1.33 billion) of total revenue. The company is exceptionally profitable, with Q4 2025 net income of $1.17 billion and a net margin of 70.84%, supported by a robust gross margin of 85.38%; however, operating margins have fluctuated between 61.8% and 67.4% over recent quarters, reflecting the high fixed-cost, scalable nature of the exchange model. Financial health is outstanding, characterized by a strong balance sheet with a low debt-to-equity ratio of 0.13, ample liquidity evidenced by a current ratio of 92.97, and massive cash generation with trailing twelve-month free cash flow of $4.19 billion, which comfortably funds substantial shareholder returns like dividends and buybacks.
Quarterly Revenue
$1.6B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.85%
Latest Quarter
Free Cash Flow
$4.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CME Overvalued?
Given the consistently positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 24.28x and a forward PE of 19.84x, with the forward discount implying the market expects modest earnings growth or a normalization from recent highs. Compared to sector averages, CME's valuation presents a mixed picture; its trailing PE of 24.28x is above typical financial data & exchange peers, but its Price-to-Sales ratio of 15.06x and EV/EBITDA of 17.05x need context from industry comps which are not provided in the data, making a precise premium/discount calculation impossible. Historically, the current trailing PE of 24.28x sits below its own 5-year peak observed in early 2022 (over 32x) but above lows seen in late 2023 (near 19x), suggesting the stock is in the mid-to-upper range of its historical valuation band, which may limit near-term multiple expansion potential absent a significant earnings acceleration.
PE
24.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 19x~37x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: CME's primary financial risk is revenue cyclicality, not solvency. While the balance sheet is robust (D/E 0.13), revenue is highly concentrated in trading fees, which showed sequential decline from Q2 to Q4 2025. Operating margins have also fluctuated between 61.8% and 67.4% in recent quarters, indicating that even this high-margin business is not immune to volume-driven earnings volatility. The high payout ratio of 97.2%, while supported by strong cash flow, leaves less room for error if earnings were to contract significantly.
Market & Competitive Risks: The foremost market risk is valuation compression. Trading at a trailing P/E of 24.3x, which is above peer averages, the stock is priced for growth. If trading volumes stagnate or the macro environment becomes less volatile, the multiple could contract towards its historical low near 19x. The stock's low beta of 0.26 is deceptive; recent underperformance shows it faces significant idiosyncratic and sector-specific headwinds, including the market's rotation away from financial infrastructure names amid uncertainty over the rate cycle. Regulatory changes impacting derivatives trading pose a persistent, though low-probability, threat.
Worst-Case Scenario: The worst-case scenario involves a combination of declining macro volatility, leading to sustained lower trading volumes, coupled with a broader market sell-off that compresses valuation multiples. This could trigger a capitulation phase where the stock breaks below its key technical support at the 52-week low of $244.56. Given the stock's recent max drawdown of -23.3% and its current proximity to lows, a realistic adverse scenario could see a further decline of 10-15% from the current price, testing levels near $220-$230. This would represent a total peak-to-trough drawdown exceeding 30% from the 52-week high of $329.16.
FAQ
The key risks are, in order of severity: 1) Revenue Cyclicality: Trading fee income, which drives over 80% of revenue, is volatile and declined sequentially last quarter, making earnings unpredictable. 2) Valuation Compression: At a premium P/E of 24.3x, the stock is vulnerable to derating if growth slows. 3) Macro Dependency: Prolonged low market volatility, perhaps from a soft economic landing, would depress trading volumes. 4) Technical Breakdown: The stock is hovering just 4.7% above its 52-week low ($244.56); a break below could trigger accelerated selling from momentum investors.
The 12-month forecast is framed by three scenarios with associated probabilities. The Base Case (50% probability) sees the stock trading between $270 and $300, assuming stable mid-single-digit revenue growth. The Bull Case (30% probability) targets $315-$335, driven by a surge in macro volatility and trading volumes. The Bear Case (20% probability) warns of a drop to $230-$250 if volatility evaporates and the valuation multiple contracts. The Base Case is most likely, anchored by CME's strong fundamentals providing a floor, but lacking a catalyst for significant multiple expansion in the near term.
CME's valuation presents a mixed picture, leaning towards fairly valued to slightly overvalued relative to near-term growth prospects. Its trailing P/E of 24.3x is above typical sector peers, indicating a premium. However, the forward P/E of 19.8x shows the market expects only modest earnings growth. Historically, the stock trades in the mid-to-upper range of its own valuation band. The current multiple implies the market is paying for stability and quality but is skeptical of significant growth acceleration. Without a clear catalyst for volume-driven earnings beats, the stock lacks a compelling valuation margin of safety.
CME is a good stock for patient, long-term investors who value business quality over short-term momentum, but it is not an obvious buy today. The company possesses an exceptional franchise with a 70.8% net margin and a fortress balance sheet. However, the stock is in a severe downtrend, down 19.3% in three months, and trades at a forward P/E of 19.8x which is not deeply discounted. For investors with a multi-year horizon willing to tolerate cyclicality, initiating a small position or dollar-cost averaging could be prudent. Traders or those seeking near-term outperformance should wait for a confirmed trend reversal.
CME is unequivocally suited for long-term investment, with a suggested minimum holding period of 3-5 years. Its business model benefits from long-term growth in global derivatives markets, and its competitive moat and pricing power are durable assets. The stock's low beta of 0.26 historically indicates lower volatility versus the market, aligning with a buy-and-hold strategy. However, its current cyclical downturn and lack of positive momentum make it a poor candidate for short-term trading. Long-term investors can collect its ~4% dividend yield while waiting for the cycle to turn.